A share price of Emergent Biosolutions Inc [EBS] is currently trading at $11.66, up 1.57%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The EBS shares have gain 16.95% over the last week, with a monthly amount glided 43.95%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Emergent Biosolutions Inc [NYSE: EBS] stock has seen the most recent analyst activity on December 30, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $15. Previously, Rodman & Renshaw started tracking the stock with Buy rating on August 22, 2024, and set its price target to $16. On March 07, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $5 on the stock. The Benchmark Company downgraded its rating to a Hold. The Benchmark Company upgraded its rating to Buy for this stock on April 10, 2023, but kept the price target unchanged to $22. In a note dated March 17, 2023, JP Morgan downgraded an Underweight rating on this stock and revised its target price from $23 to $9.
Emergent Biosolutions Inc experienced fluctuations in its stock price throughout the past year between $1.42 and $15.10. Currently, Wall Street analysts expect the stock to reach $51.5 within the next 12 months. Emergent Biosolutions Inc [NYSE: EBS] shares were valued at $11.66 at the most recent close of the market. An investor can expect a potential return of 341.68% based on the average EBS price forecast.
Analyzing the EBS fundamentals
Trailing Twelve Months sales for Emergent Biosolutions Inc [NYSE:EBS] were 1.13B which represents 8.61% growth. Gross Profit Margin for this corporation currently stands at 0.29% with Operating Profit Margin at -0.09%, Pretax Profit Margin comes in at -0.15%, and Net Profit Margin reading is -0.19%. To continue investigating profitability, this company’s Return on Assets is posted at -0.14, Equity is -0.38 and Total Capital is -0.08. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.37 points at the first support level, and at 11.07 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.97, and for the 2nd resistance point, it is at 12.27.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Emergent Biosolutions Inc [NYSE:EBS] is 2.88. Further, the Quick Ratio stands at 1.47, while the Cash Ratio is 0.65. Considering the valuation of this stock, the price to sales ratio is 0.56, the price to book ratio is 1.24.
Transactions by insiders
Recent insider trading involved DeGolyer Donald W, Director, that happened on Nov 12 ’24 when 25000.0 shares were sold. Director, White Marvin L completed a deal on Nov 11 ’24 to sell 14287.0 shares. Meanwhile, Director DeGolyer Donald W bought 25000.0 shares on Nov 12 ’24.
